| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.55(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,939 |
| 52
Week Range: |
$11.44 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
661,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$8,435,402 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
11 |
12 |
| Total Shares Sold |
0 |
10,994 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$153,810 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tyree James L |
Director |
– • – |
2014-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
21,670 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2014-11-04 |
4 |
B |
$12,786,500.00 |
$2,147,483,647 |
I/I |
832,456 |
31,581,179 |
1.5 |
- |
|
| Kearney Terrence C |
Director |
– • – |
2014-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
23,133 |
23,133 |
|
- |
|
| Desparbes Eric |
SVP and CFO |
• – – |
2014-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
102,471 |
102,471 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
401,538 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
262,198 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
443,013 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
334,040 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2014-08-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(96,250) |
825,391 |
|
- |
|
| Aguiar Michael W |
President & CEO |
• • – |
2014-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,905 |
288,840 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2014-08-13 |
4 |
S |
$22.50 |
$1,202,040 |
D/D |
(53,424) |
265,459 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2014-08-13 |
4 |
OE |
$9.81 |
$926,264 |
D/D |
74,441 |
318,883 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-08-12 |
4 |
S |
$22.30 |
$23,370 |
D/D |
(1,048) |
446,274 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-08-11 |
4 |
S |
$22.12 |
$599,629 |
D/D |
(27,108) |
447,322 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-08-11 |
4 |
OE |
$14.53 |
$489,182 |
D/D |
33,667 |
474,430 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2014-08-11 |
4 |
B |
$3,912,270.00 |
$2,147,483,647 |
I/I |
172,651 |
30,748,723 |
1.5 |
- |
|
| Abercrombie George B |
Sr. VP, Corp. Partnerships |
• – – |
2014-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,855 |
244,442 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,365 |
440,763 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
62,403 |
921,641 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,365 |
337,301 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,365 |
244,935 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,365 |
404,799 |
|
- |
|
| Pepe Paul |
Director |
– • – |
2014-06-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
15,170 |
15,170 |
|
- |
|
| Friedman Cathy |
Director |
– • – |
2014-06-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
15,170 |
15,170 |
|
- |
|
283 Records found
|
|
Page 10 of 12 |
|
|
0.27 (1.8%) 
